Allosteric conformational change is an important paradigm in the regulation of protein function, which is typically triggered by the binding of small cofactors, metal ions or protein partners. Here, we found those conformational transitions can be effectively monitored by F NMR, facilitated by a site-specific F incorporation strategy at the protein C-terminus using asparaginyl endopeptidase (AEP). Three case studies show that C-terminal F-nuclei can reveal protein dynamics not only adjacent but also distal to C-terminus, including those occurring in a hemoprotein neuroglobin (Ngb), calmodulin (CaM), and a cobalt metalloregulator (CoaR) responding to both cobalt and tetrapyrrole. In Ngb, the heme orientation disorder is affected by missense mutations that perturb backbone rigidity or surface charges close to the heme axial ligands. In CaM, the C-terminal F-nuclei is an ideal probe for detecting the binding states of Ca, peptides and inhibitors. Furthermore, multiple F-moieties were incorporated into the two domains of CoaR, revealing the intrinsically disordered C-terminal metal binding tail might be an allosteric conformational switch to maintain cobalt homeostasis and balance corrinoid biosynthesis. This study demonstrates that the AEP-based F-modification strategy can be applied to various targets to study allosteric regulation, especially for those biological processes modulated by the protein C-terminus.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615248 | PMC |
http://dx.doi.org/10.1038/s42003-024-07331-x | DOI Listing |
J Hepatol
January 2025
Department of Surgery, Sir Y.K. Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Electronic address:
Background & Aims: The ubiquitin receptor ADRM1/Rpn13 governs the specificity of eukaryotic protein degradation. By SMRT sequencing, we first discovered a novel spliced variant of ADRM1 with a skipped exon 9, termed ADRM1-ΔEx9, in human hepatocellular carcinoma (HCC). This study aimed to elucidate this novel ubiquitin receptor's underlying biology and clinical implications in HCC.
View Article and Find Full Text PDFBackground: Abnormal protein depositions of amyloid β and tau are present in the nasal cavity in patients with Alzheimer’s disease. This finding raises an idea that nasal tissues would be a promising source of diagnostic biomarkers for Alzheimer’s disease. However, the amounts of amyloid β and tau are extremely small, making it difficult to quantify the levels using conventional methods such as ELISA, and thus it is challenging to utilize them for the diagnostic biomarkers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Kentucky College of Medicine, Sanders‐Brown Center on Aging, Lexington, KY, USA
Background: Our lab recently developed 2 mouse monoclonal antibodies that preferentially react with “distressed astrocytes”. One monoclonal, 26A6, was found to react preferentially with a form of the Ca2+/calmodulin‐dependent protein phosphatase, calcineurin (CN), that has been cleaved by calpain, to generate a 48 kDa CN fragment (∆CN). We recently published a characterization of this antibody.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pittsburgh, Pittsburgh, PA, USA
Background: Microglia play a crucial role in clearing amyloid‐beta (Aβ) plaques, one of the primary pathological hallmarks of AD. We previously showed that G protein‐biased signaling by the G protein‐coupled receptor GPR3 reduces soluble Aβ levels and leads to an increase in Aβ plaque compaction and a reduction in Aβ plaque area in the preclinical AD mouse model. These results suggest a protective microglial response that may limit Aβ plaque formation in G protein‐biased GPR3 AD mice.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea, Republic of (South)
Background: Abnormal aggregation and accumulation of tau is a hallmark of tauopathy including Alzheimer’s disease. Effective targeting of tau for therapeutic purposes requires a clear understanding of its epitope landscape with identification of a key pathogenic tau species. Despite numerous proposed and tested tau epitopes, ranging from the N‐terminus to the microtubule‐binding region and C‐terminus, the most effective target remains elusive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!